Cargando…

Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?

BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavarsad Shahripour, Reza, Mortazavi, Martin M., Barlinn, Kristian, Keikhaei, Bijan, Mousakhani, Hadi, Azarpazhooh, Mahmoud Reza, Oghbaee, Morteza, Sajedi, Seyed Aidin, Kepplinger, Jessica, Tubbs, R. Shane, Albright, Karen C., Alexandrov, Andrei V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Stroke Society 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060272/
https://www.ncbi.nlm.nih.gov/pubmed/24949316
http://dx.doi.org/10.5853/jos.2014.16.2.97
_version_ 1782321349598904320
author Bavarsad Shahripour, Reza
Mortazavi, Martin M.
Barlinn, Kristian
Keikhaei, Bijan
Mousakhani, Hadi
Azarpazhooh, Mahmoud Reza
Oghbaee, Morteza
Sajedi, Seyed Aidin
Kepplinger, Jessica
Tubbs, R. Shane
Albright, Karen C.
Alexandrov, Andrei V.
author_facet Bavarsad Shahripour, Reza
Mortazavi, Martin M.
Barlinn, Kristian
Keikhaei, Bijan
Mousakhani, Hadi
Azarpazhooh, Mahmoud Reza
Oghbaee, Morteza
Sajedi, Seyed Aidin
Kepplinger, Jessica
Tubbs, R. Shane
Albright, Karen C.
Alexandrov, Andrei V.
author_sort Bavarsad Shahripour, Reza
collection PubMed
description BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is unclear if the same flow velocity cut-offs can be applied to the Iranian population. We aimed to evaluate baseline TCD findings in Iranian children with SCD and no prior strokes. METHODS: Children with genetically confirmed SCD (Arabian haplotype, homozygote) and without SCD (controls) were prospectively recruited from pediatric outpatient clinic over a period of 9 months. We performed TCD in both groups to determine flow velocities in the middle cerebral (MCA) and terminal internal carotid arteries (TICA). RESULTS: Of 74 screened children, 60 met the inclusion/exclusion criteria (62% female; mean age 10±4 years). Baseline characteristics did not differ between the cases and controls, except hemoglobin (Hb) which was significantly lower in the SCD group (P<0.001). The right MCA TAMM (Time Averaged Maximum Mean) was significantly higher than in controls (125+5.52 cm/s vs. 92.5+1.63 cm/s, P<0.001). Left MCA did not show differences. The TICA TAMM was also different between cases and controls (P<0.05). CONCLUSIONS: Among Iranian children with asymptomatic SCD and without receiving recent transfusion TCD velocities are higher as compared to healthy controls but appear much lower than those observed in STOP (Stroke Prevention Trial in Sickle Cell Anemia) studies. We hypothesize that some children at high risk may be present with velocities lower than 170-200 cm/s thresholds. A prospective validation of ethnicity-specific prognostic criteria is warranted.
format Online
Article
Text
id pubmed-4060272
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Stroke Society
record_format MEDLINE/PubMed
spelling pubmed-40602722014-06-19 Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease? Bavarsad Shahripour, Reza Mortazavi, Martin M. Barlinn, Kristian Keikhaei, Bijan Mousakhani, Hadi Azarpazhooh, Mahmoud Reza Oghbaee, Morteza Sajedi, Seyed Aidin Kepplinger, Jessica Tubbs, R. Shane Albright, Karen C. Alexandrov, Andrei V. J Stroke Original Article BACKGROUND AND PURPOSE: Sickle cell disease (SCD) is strongly linked to stroke across all haplotypes in the pediatric population. Transcranial Doppler (TCD) ultrasound is known to identify the highest risk group in African-Americans who need to receive and stay on blood transfusions, but it is unclear if the same flow velocity cut-offs can be applied to the Iranian population. We aimed to evaluate baseline TCD findings in Iranian children with SCD and no prior strokes. METHODS: Children with genetically confirmed SCD (Arabian haplotype, homozygote) and without SCD (controls) were prospectively recruited from pediatric outpatient clinic over a period of 9 months. We performed TCD in both groups to determine flow velocities in the middle cerebral (MCA) and terminal internal carotid arteries (TICA). RESULTS: Of 74 screened children, 60 met the inclusion/exclusion criteria (62% female; mean age 10±4 years). Baseline characteristics did not differ between the cases and controls, except hemoglobin (Hb) which was significantly lower in the SCD group (P<0.001). The right MCA TAMM (Time Averaged Maximum Mean) was significantly higher than in controls (125+5.52 cm/s vs. 92.5+1.63 cm/s, P<0.001). Left MCA did not show differences. The TICA TAMM was also different between cases and controls (P<0.05). CONCLUSIONS: Among Iranian children with asymptomatic SCD and without receiving recent transfusion TCD velocities are higher as compared to healthy controls but appear much lower than those observed in STOP (Stroke Prevention Trial in Sickle Cell Anemia) studies. We hypothesize that some children at high risk may be present with velocities lower than 170-200 cm/s thresholds. A prospective validation of ethnicity-specific prognostic criteria is warranted. Korean Stroke Society 2014-05 2014-05-30 /pmc/articles/PMC4060272/ /pubmed/24949316 http://dx.doi.org/10.5853/jos.2014.16.2.97 Text en Copyright © 2014 Korean Stroke Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bavarsad Shahripour, Reza
Mortazavi, Martin M.
Barlinn, Kristian
Keikhaei, Bijan
Mousakhani, Hadi
Azarpazhooh, Mahmoud Reza
Oghbaee, Morteza
Sajedi, Seyed Aidin
Kepplinger, Jessica
Tubbs, R. Shane
Albright, Karen C.
Alexandrov, Andrei V.
Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title_full Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title_fullStr Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title_full_unstemmed Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title_short Can STOP Trial Velocity Criteria Be Applied to Iranian Children with Sickle Cell Disease?
title_sort can stop trial velocity criteria be applied to iranian children with sickle cell disease?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060272/
https://www.ncbi.nlm.nih.gov/pubmed/24949316
http://dx.doi.org/10.5853/jos.2014.16.2.97
work_keys_str_mv AT bavarsadshahripourreza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT mortazavimartinm canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT barlinnkristian canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT keikhaeibijan canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT mousakhanihadi canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT azarpazhoohmahmoudreza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT oghbaeemorteza canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT sajediseyedaidin canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT kepplingerjessica canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT tubbsrshane canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT albrightkarenc canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease
AT alexandrovandreiv canstoptrialvelocitycriteriabeappliedtoiranianchildrenwithsicklecelldisease